The threat of antibiotic- resistant microbes poses one of the biggest economic and health threats in our time, as microbes are becoming more resistant and fewer drugs are passing clinical trials successfully.
Moreover, the increase in global migration accelerates the spread as we have seen from Mers and Ebola viruses, as well as overconsumption and hospital acquired infections.
Thus, our 18th year in hosting
Superbugs and Superdrugs continues to address the core challenges in the industry from: Investment, R&D to hospital hygiene, and consumer engagement and review current strategies.
We're now seeing strong leaderships and collaborations to fund research and investment from the likes of: The Welcome Trust, IMI, and BARDA who are invited to share their funding strategies to strengthen the antiobiotics pipeline.
Benefits of Attending
Our 2016 program will feature new updates on global collaborations and funding schemes: Case study reviews of strategies designed to best adapt with emerging threats and changing economies.
In addition, further insight into mechanism of infectious activity as well as robust screening and modelling tools to mimic bacterial structure will add fresh insight in R&D and drug development
Key topics new for 2016 include:
- Extending portfolio partnerships to strengthen the antibiotic
- Expansion of the COMBACTE project and European clinical trial network
- Smart antimicrobials to combat HAI's and inhibit biofilm-derived infections
- Harnessing genomics and host -pathogen relationships to control of viral infections
Plus An Interactive Half-Day Pre-Conference Workshop | Tuesday 15th March 2016
Rapid Diagnostic Tools for Infectious DiseasesWorkshop Leader: Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd
8.30am - 12.30pm
Speakers
- Andrew Cross, Director, ACT-Surfaces Lrd
- Ankit Mahadevia, President and CEO, Spero Therapeutics
- Anna Norrby-Teglund, Professor, Head of Center for Infectious Medicine, Karolinska Institutet
- Arjon Van Hengel, Scientific Officer, European Commission
- Christopher Houchens, Project Officer, BARDA
- Conrad Lichenstein, Chief Scientific Officer, Nemesis Bioscience
- David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd.
- Eszter Nagy, Co-founder, President and CSO, Arsanis Biosciences
- Frank Schuren, Senior Scientist, TNO Pharma
- Jean de Gunzburg, Chief Scientific Officer, Da Volterra
- Jean-Pierre Paccaud, Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
- Jorge Mestre-Ferrandiz, Director, Office of Health Economics (OHE)
- Lloyd Czaplewski, Director, Chemical Biology Ventures
- Ole Hyldegaard, Medical Director, Associate Professor, University Hospital of Copenhagen
- Prabhavathi Fernandes, President and Chief Executive Officer, Cempra Pharmaceuticals
- Richard Bax, Senior Partner, TranScrip Partners
- Sam Whitehouse, Chief Operating Officer, QuantuMDX Group
- Steve Boakes, Head of Microbiology, Cantab Anti-infectives
- William Hope, Professor of Therapeutics and Infectious Diseases, University Of Liverpool
- William J. Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Venue
Holiday Inn Kensington Forum97 Cromwell Rd,
London, SW7 4DN
United Kingdom
